Optimal multi-stage designs for a phase II trial that permits one dose escalation

Area of Science:

• Clinical Trials Methodology
• Biostatistics
• Pharmacology

Background:

• Simon's two-stage design is a standard for single-dose phase II clinical trials.
• Existing designs may not efficiently accommodate dose escalation based on early efficacy signals.

Purpose of the Study:

• To develop and present optimal multi-stage clinical trial designs for testing a low dose of an experimental drug.
• To allow for a single dose escalation during the trial if the low dose proves ineffective.
• To enhance the efficiency of phase II clinical trials with potential dose escalation.

Main Methods:

• Extension of Simon's optimal two-stage design methodology.
• Development of optimal multi-stage designs incorporating a single dose escalation step.
• Focus on efficacy as the primary endpoint, assuming known toxicity profiles.

Main Results:

• The proposed multi-stage designs are more efficient than conducting two separate Simon optimal trials.
• These designs provide a structured approach for dose escalation in phase II trials.
• Efficiency gains are realized by optimizing the trial flow based on early efficacy data.

Conclusions:

• The presented optimal multi-stage designs offer a more efficient alternative for phase II trials requiring potential dose escalation.
• These designs are suitable when the primary goal is to assess drug efficacy and toxicity is well-characterized.
• Researchers can improve resource utilization in early-phase drug development with these advanced methodologies.